title: Visceral leishmaniasis during pegylated interferon therapy for chronic hepatitis C: first report.
authors.forename: Antonio
authors.initials: A
authors.lastname: Cascio
authors.forename: Spinello
authors.initials: S
authors.lastname: Antinori
authors.forename: Filippo
authors.initials: F
authors.lastname: Ricciardi
authors.forename: Giuseppo
authors.initials: G
authors.lastname: Costantino
authors.forename: Chiara
authors.initials: C
authors.lastname: Iaria
mesh_terms: D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D007898:Leishmaniasis, Visceral / Q000139:chemically induced* / Q000188:drug therapy; D008297:Male; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use; D011994:Recombinant Proteins
chemical_list: D000981:Antiprotozoal Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D000666:Amphotericin B; C100416:peginterferon alfa-2a